HC Wainwright began coverage on shares of Miragen Therapeutics (NASDAQ:MGEN) in a research report released on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $3.00 target price on the medical research company’s stock.

MGEN has been the subject of several other reports. ValuEngine upgraded Miragen Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded Miragen Therapeutics from a hold rating to a strong-buy rating and set a $1.25 price objective for the company in a research report on Tuesday, August 13th. Finally, Wedbush restated a buy rating and set a $24.00 price objective on shares of Miragen Therapeutics in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $13.15.

Shares of Miragen Therapeutics stock opened at $1.23 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.26 and a quick ratio of 5.26. Miragen Therapeutics has a 1 year low of $0.78 and a 1 year high of $6.42. The company has a market capitalization of $42.22 million, a P/E ratio of -1.12 and a beta of 1.12. The business has a 50 day moving average price of $1.79 and a 200 day moving average price of $2.50.

Miragen Therapeutics (NASDAQ:MGEN) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.08. Miragen Therapeutics had a negative return on equity of 85.50% and a negative net margin of 925.52%. The firm had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.89 million. As a group, research analysts expect that Miragen Therapeutics will post -1.15 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its holdings in Miragen Therapeutics by 3.4% in the 4th quarter. BlackRock Inc. now owns 1,459,881 shares of the medical research company’s stock valued at $4,423,000 after acquiring an additional 48,128 shares during the last quarter. Vanguard Group Inc. raised its holdings in Miragen Therapeutics by 37.7% in the 2nd quarter. Vanguard Group Inc. now owns 617,914 shares of the medical research company’s stock valued at $1,267,000 after acquiring an additional 169,086 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Miragen Therapeutics by 10.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 359,243 shares of the medical research company’s stock valued at $794,000 after acquiring an additional 33,557 shares during the last quarter. Geode Capital Management LLC raised its holdings in Miragen Therapeutics by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 230,127 shares of the medical research company’s stock valued at $697,000 after acquiring an additional 11,541 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Miragen Therapeutics by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 216,866 shares of the medical research company’s stock valued at $657,000 after buying an additional 4,404 shares during the period. Institutional investors own 37.35% of the company’s stock.

Miragen Therapeutics Company Profile

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Further Reading: What is the Coverage Ratio?

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.